These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29949213)

  • 21. Kratom use disorder: a primer for primary care physicians.
    Groff D; Stuckey H; Philpott C; Van Dyke E; Silvis M; Leong SL; Bone C
    J Addict Dis; 2022; 40(1):131-141. PubMed ID: 34281482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.
    Henningfield JE; Fant RV; Wang DW
    Psychopharmacology (Berl); 2018 Feb; 235(2):573-589. PubMed ID: 29273821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.
    Avery BA; Boddu SP; Sharma A; Furr EB; Leon F; Cutler SJ; McCurdy CR
    Planta Med; 2019 Mar; 85(4):340-346. PubMed ID: 30452072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to 'kratom'.
    Davidson L; Rawat M; Stojanovski S; Chandrasekharan P
    J Neonatal Perinatal Med; 2019; 12(1):109-112. PubMed ID: 30149482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature.
    Ahmad J; Odin JA; Hayashi PH; Fontana RJ; Conjeevaram H; Avula B; Khan IA; Barnhart H; Vuppalanchi R; Navarro VJ;
    Drug Alcohol Depend; 2021 Jan; 218():108426. PubMed ID: 33257199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction.
    Hassan Z; Muzaimi M; Navaratnam V; Yusoff NH; Suhaimi FW; Vadivelu R; Vicknasingam BK; Amato D; von Hörsten S; Ismail NI; Jayabalan N; Hazim AI; Mansor SM; Müller CP
    Neurosci Biobehav Rev; 2013 Feb; 37(2):138-51. PubMed ID: 23206666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Motives for using Kratom (Mitragyna speciosa Korth.) among regular users in Malaysia.
    Singh D; Narayanan S; Müller CP; Swogger MT; Chear NJY; Dzulkapli EB; Yusoff NSM; Ramachandram DS; León F; McCurdy CR; Vicknasingam B
    J Ethnopharmacol; 2019 Apr; 233():34-40. PubMed ID: 30594604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel case of maternal and neonatal kratom dependence and withdrawal.
    Mackay L; Abrahams R
    Can Fam Physician; 2018 Feb; 64(2):121-122. PubMed ID: 29449242
    [No Abstract]   [Full Text] [Related]  

  • 29. Social Functioning of Kratom (Mitragyna speciosa) Users in Malaysia.
    Singh D; Müller CP; Vicknasingam BK; Mansor SM
    J Psychoactive Drugs; 2015; 47(2):125-31. PubMed ID: 25950592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DARK Classics in Chemical Neuroscience: Kratom.
    Han C; Schmitt J; Gilliland KM
    ACS Chem Neurosci; 2020 Jan; ():. PubMed ID: 31841631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kratom Withdrawal: A Systematic Review with Case Series.
    Stanciu CN; Gnanasegaram SA; Ahmed S; Penders T
    J Psychoactive Drugs; 2019; 51(1):12-18. PubMed ID: 30614408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia.
    Singh D; Müller CP; Murugaiyah V; Hamid SBS; Vicknasingam BK; Avery B; Chear NJY; Mansor SM
    J Ethnopharmacol; 2018 Mar; 214():197-206. PubMed ID: 29248450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of Mitragyna speciosa extract, mitragynine, and opioid agonists on thermal nociception in rats.
    Carpenter JM; Criddle CA; Craig HK; Ali Z; Zhang Z; Khan IA; Sufka KJ
    Fitoterapia; 2016 Mar; 109():87-90. PubMed ID: 26688378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-Report Data on Regular Consumption of Illicit Drugs and HIV Risk Behaviors after Kratom (
    Saref A; Suraya S; Singh D; Grundmann O; Narayanan S; Swogger MT; Prozialeck WC; Boyer E; Balasingam V
    J Psychoactive Drugs; 2020; 52(2):138-144. PubMed ID: 31682782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experiences of Kratom Users: A Qualitative Analysis.
    Swogger MT; Hart E; Erowid F; Erowid E; Trabold N; Yee K; Parkhurst KA; Priddy BM; Walsh Z
    J Psychoactive Drugs; 2015; 47(5):360-7. PubMed ID: 26595229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence.
    McWhirter L; Morris S
    Eur Addict Res; 2010; 16(4):229-31. PubMed ID: 20798544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom.
    Tobacyk J; Parks BJ; Lovelady N; Brents LK
    Int J Drug Policy; 2022 Oct; 108():103817. PubMed ID: 35952436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of regular kratom (
    Leong Bin Abdullah MFI; Yuvashnee N; Singh D
    Subst Abus; 2021; 42(4):444-449. PubMed ID: 33617750
    [No Abstract]   [Full Text] [Related]  

  • 39. Kratom.
    Sanderson M; Rowe A
    CMAJ; 2019 Oct; 191(40):E1105. PubMed ID: 31591097
    [No Abstract]   [Full Text] [Related]  

  • 40. Think Kratom Is a Safe Opioid Substitute? Think Again!: History, Evidence, and Possible Future for Mitragyna speciosa.
    O'Malley PA
    Clin Nurse Spec; 2018; 32(5):227-230. PubMed ID: 30095521
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.